Hence, the anti-CTLA4 antibody ipilimumab (10 mg/kg) plus dacarbazine significantly prolonged overall survival (11.2 vs. 9.1 months; HR 0.72; p < 0.001) compared to dacarbazine alone for patients with untreated metastatic melanoma [82]. The gene discussed is CTLA4; the disease is metastatic melanoma.